Kuros Biosciences Ltd. (CH:KURN)
:KURN
Want to see CH:KURN full AI Analyst Report?
KURN Stock Chart & Stats
CHF28.16
-CHF0.35(-1.68%)
At close: 4:00 PM EST
CHF28.16
-CHF0.35(-1.68%)
Day’s Range― - ―
52-Week RangeCHF18.37 - CHF34.20
Previous CloseN/A
Volume98.33K
Average Volume (3M)128.87K
Market Cap
CHF808.51M
Enterprise ValueCHF829.33M
Total Cash (Recent Filing)CHF15.66M
Total Debt (Recent Filing)CHF3.94M
Price to Earnings (P/E)490.3
Beta1.39
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding39,439,423
10 Day Avg. Volume110,510
30 Day Avg. Volume128,868
Financial Highlights & Ratios
PEG Ratio-3.21
Price to Book (P/B)15.78
Price to Sales (P/S)8.71
P/FCF Ratio-439.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF38.00Price Target Upside34.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.31
Revenue Forecast (FY)CHF200.67M
Bulls Say, Bears Say
Bulls Say
Revenue Scaling & Market AdoptionSustained multi-year revenue expansion indicates durable surgical adoption of MagnetOs and growing share in orthobiologics. Scaling revenue increases fixed-cost leverage and supports continued commercial investment, bolstering long-term top-line resilience across geographies and indications.
High Gross MarginsVery high gross margins reflect strong product economics and likely proprietary or manufacturing advantages. Durable margin structure gives room to fund R&D and sales expansion while protecting operating profits from cost swings, supporting sustainable profitability as volumes grow.
Conservative Balance Sheet / Low LeverageVery low leverage provides financial flexibility to fund commercialization or clinical work without immediate refinancing pressure. A conservative balance sheet reduces default risk, supports M&A or geographic expansion optionality, and improves resilience to cyclical dental/spine demand shifts.
Bears Say
Negative Cash Conversion In 2025Cash-generation weakness despite accounting profits signals working-capital or investment timing pressures. Persistent negative operating or free cash flow erodes liquidity, increases reliance on external funding, and can force slower organic growth or higher-cost capital if not corrected.
Thin Net Profitability MarginMargins converted to the bottom line remain slim, leaving limited buffer against pricing pressure, reimbursement changes, or higher SG&A as the company scales. Thin net profitability makes returns sensitive to small revenue or cost swings and constrains free-cash-flow upside.
Near-term Funding Sensitivity If Negative FCF PersistsNegative free cash flow in the face of growth raises the probability of needing external capital to sustain commercial expansion or R&D. That reliance could lead to dilutive equity raises or higher-cost debt, reducing strategic optionality and pressuring long-term return metrics if recurring.
Kuros Biosciences News
KURN FAQ
What was Kuros Biosciences Ltd.’s price range in the past 12 months?
Kuros Biosciences Ltd. lowest stock price was CHF18.37 and its highest was CHF34.20 in the past 12 months.
What is Kuros Biosciences Ltd.’s market cap?
Kuros Biosciences Ltd.’s market cap is CHF808.51M.
When is Kuros Biosciences Ltd.’s upcoming earnings report date?
Kuros Biosciences Ltd.’s upcoming earnings report date is Aug 13, 2026 which is in 59 days.
How were Kuros Biosciences Ltd.’s earnings last quarter?
Kuros Biosciences Ltd. released its earnings results on Mar 10, 2026. The company reported CHF0.093 earnings per share for the quarter, beating the consensus estimate of CHF0 by CHF0.093.
Is Kuros Biosciences Ltd. overvalued?
According to Wall Street analysts Kuros Biosciences Ltd.’s price is currently Undervalued.
Does Kuros Biosciences Ltd. pay dividends?
Kuros Biosciences Ltd. does not currently pay dividends.
What is Kuros Biosciences Ltd.’s EPS estimate?
Kuros Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kuros Biosciences Ltd. have?
Kuros Biosciences Ltd. has 39,439,423 shares outstanding.
What happened to Kuros Biosciences Ltd.’s price movement after its last earnings report?
Kuros Biosciences Ltd. reported an EPS of CHF0.093 in its last earnings report, beating expectations of CHF0. Following the earnings report the stock price went up 10.609%.
Which hedge fund is a major shareholder of Kuros Biosciences Ltd.?
Currently, no hedge funds are holding shares in CH:KURN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kuros Biosciences Ltd.
Kuros Biosciences AG functions as a biopharmaceutical enterprise, dedicated to both the development and market introduction of advanced therapeutic solutions for tissue regeneration and bone repair. Its operations span across the United States, the European Union, and other global regions. The company's business activities are structured into three main segments: Medical Devices, Pharmaceuticals, and a Legacy Portfolio. Its orthobiologics product line includes MagnetOs Granules and MagnetOs Putty, available in EU and US markets for various orthopedic, spinal, and dental applications. Within its fibrin/PTH orthobiologics pipeline, KUR-111 has successfully completed a Phase 2b clinical trial for treating tibial plateau fractures. Similarly, KUR-113 has concluded its Phase 2b clinical trial for tibial shaft fractures and is currently undergoing a Phase II trial for spinal interbody fusion procedures. Additionally, Kuros offers sealant products such as Neuroseal, a synthetic tissue sealant marketed in the EU and US, engineered to prevent cerebrospinal fluid leakage after cranial or spinal surgeries. The company also engages in a collaborative endeavor with Checkmate Pharmaceuticals LLC for the advancement of CYT003, intended for oncology treatments. Kuros Biosciences AG is headquartered in Schlieren, Switzerland.
KURN Company Deck
KURN Earnings Call
Q4 2026
0:00 / 0:00
KURN Stock 12 Month Forecast
Average Price Target
CHF38.00
▲(34.94% Upside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Idorsia Ltd
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―
Options Prices
Currently, No data available
---